# Study Evaluating Single Ascending Doses of AAB-001 Vaccine SAD Japanese Patients With Alzheimers Disease

> **NCT00397891** · PHASE1 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 80 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** bapineuzumab
- **DRUG:** bapineuzumab
- **DRUG:** bapineuzumab

## Key facts

- **NCT ID:** NCT00397891
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2010-02
- **Final completion:** 2010-02
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2014-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00397891

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00397891, "Study Evaluating Single Ascending Doses of AAB-001 Vaccine SAD Japanese Patients With Alzheimers Disease". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00397891. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*